Disease · MONDO_0006130
central nervous system neoplasm
6 sourcesdiseases-2026-09-18-0.1.0
Download JSON
Cite this record
ConductScience Library. central nervous system neoplasm. Diseases, record MONDO_0006130. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0006130
On this page
Disease
Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.
- Other names
CNS neoplasm, CNS tumor, CNS tumour, brain/spinal cord tumor, brain/spinal cord tumour, central nervous system neoplasm (disease), central nervous system tumor, central nervous system tumour, neoplasm of CNS, neoplasm of central nervous system, neoplasm of the central nervous system, tumor of CNS, tumor of central nervous system, tumor of the CNS, tumor of the central nervous system, tumour of CNS, tumour of central nervous system, tumour of the CNS, tumour of the central nervous system
- Open Targets
Drugs75
The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Drug | ChEMBL ID | Type | Open Targets' stage | Stage reported by | Reports | Of them trials | Trials shown here | Source |
|---|---|---|---|---|---|---|---|---|
| TEMOZOLOMIDE | CHEMBL810 | Small molecule | Phase 2 | ClinicalTrials.gov | 9 | 9 | 9 | Drugs and targets |
| IRINOTECAN | CHEMBL481 | Small molecule | Phase 2 | ClinicalTrials.gov | 5 | 5 | 5 | Drugs and targets |
| ETOPOSIDE | CHEMBL44657 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| MELPHALAN | CHEMBL852 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| THIOTEPA | CHEMBL671 | Small molecule | Phase 2 | ClinicalTrials.gov | 3 | 3 | 3 | Drugs and targets |
| ALECTINIB | CHEMBL1738797 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CABOZANTINIB | CHEMBL2105717 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| CARBOPLATIN | CHEMBL1351 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| ENTRECTINIB | CHEMBL1983268 | Small molecule | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
| IPILIMUMAB | CHEMBL1789844 | Antibody | Phase 2 | ClinicalTrials.gov | 2 | 2 | 2 | Drugs and targets |
1 to 10 of 75
See all 75 drugsTargets140
The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.
| Target | Protein | Its drugs that act on it | Mechanisms | Highest stage of those drugs | Gene in Genes | Source |
|---|---|---|---|---|---|---|
| CRBN | CRL4(CRBN) E3 ubiquitin ligase | 3 | CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | Phase 1 | https://conductscience.org/library/genes/51185 | Drugs and targets |
| CUL4A | CRL4(CRBN) E3 ubiquitin ligase | 3 | CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | Phase 1 | https://conductscience.org/library/genes/8451 | Drugs and targets |
| DDB1 | CRL4(CRBN) E3 ubiquitin ligase | 3 | CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | Phase 1 | https://conductscience.org/library/genes/1642 | Drugs and targets |
| HDAC1 | Histone deacetylase | 3 | Histone deacetylase 1 inhibitor; Histone deacetylase inhibitor | Phase 1 | https://conductscience.org/library/genes/3065 | Drugs and targets |
| HDAC2 | Histone deacetylase | 3 | Histone deacetylase 2 inhibitor; Histone deacetylase inhibitor | Phase 1 | https://conductscience.org/library/genes/3066 | Drugs and targets |
| HDAC3 | Histone deacetylase | 3 | Histone deacetylase 3 inhibitor; Histone deacetylase inhibitor | Phase 1 | https://conductscience.org/library/genes/8841 | Drugs and targets |
| HDAC6 | Histone deacetylase | 3 | Histone deacetylase 6 inhibitor; Histone deacetylase inhibitor | Phase 1 | https://conductscience.org/library/genes/10013 | Drugs and targets |
| KDR | Vascular endothelial growth factor receptor | 3 | Vascular endothelial growth factor receptor 2 inhibitor; Vascular endothelial growth factor receptor inhibitor | Phase 2 | https://conductscience.org/library/genes/3791 | Drugs and targets |
| RBX1 | CRL4(CRBN) E3 ubiquitin ligase | 3 | CRL4(CRBN) E3 ubiquitin ligase inhibitor; CRL4(CRBN) E3 ubiquitin ligase modulator | Phase 1 | https://conductscience.org/library/genes/9978 | Drugs and targets |
| TOP1 | DNA topoisomerase 1 | 3 | DNA topoisomerase I inhibitor | Phase 2 | https://conductscience.org/library/genes/7150 | Drugs and targets |
1 to 10 of 140
See all 140 targetsTrials58
Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs. 2 more are not shown, since the checks do not confirm them.
| Trial | Title | Phase | Participants | Results first posted | Conditions | Drugs | Linked by | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03130959 | A Study to Evaluate the Safety and Efficacy of Nivolumab Monotherapy and Nivolumab in Combination With Ipilimumab in Pediatric Participants With High Grade Primary Central Nervous System (CNS) Malignancies | Phase 2 | 166 | 2021-04-01 | Various Advanced Cancer | IPILIMUMAB, NIVOLUMAB | Its record names the disease | ClinicalTrials.gov |
| NCT02323880 | Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas | Phase 1 | 59 | 2024-01-02 | Malignant Glioma, Recurrent Brain Neoplasm, Recurrent Childhood Central Nervous System Neoplasm, Recurrent Childhood Glioblastoma, Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm, WHO Grade 3 Glioma | SELINEXOR | Its record names the disease | ClinicalTrials.gov |
| NCT03690869 | REGN2810 in Pediatric Patients With Relapsed, Refractory Solid, or Central Nervous System (CNS) Tumors and Safety and Efficacy of REGN2810 in Combination With Radiotherapy in Pediatric Patients With Newly Diagnosed or Recurrent Glioma | Phase 1/2 | 57 | 2024-10-09 | Relapsed Solid Tumor, Refractory Solid Tumor, Relapsed Central Nervous System Tumor, Refractory Central Nervous System Tumor, Diffuse Intrinsic Pontine Glioma, High Grade Glioma | CEMIPLIMAB | Its record names the disease | ClinicalTrials.gov |
| NCT01709435 | Cabozantinib S-Malate in Treating Younger Patients With Recurrent or Refractory Solid Tumors | Phase 1 | 41 | 2023-12-21 | Recurrent Malignant Solid Neoplasm, Recurrent Melanoma, Recurrent Primary Central Nervous System Neoplasm, Recurrent Thyroid Gland Carcinoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm, Thyroid Gland Medullary Carcinoma | CABOZANTINIB | Its record names the disease | ClinicalTrials.gov |
| NCT02255461 | Palbociclib Isethionate in Treating Younger Patients With Recurrent, Progressive, or Refractory Central Nervous System Tumors | Phase 1 | 35 | 2020-04-08 | Childhood Choroid Plexus Tumor, Childhood Ependymoblastoma, Childhood Grade III Meningioma, Childhood High-grade Cerebellar Astrocytoma, Childhood High-grade Cerebral Astrocytoma, Childhood Medulloepithelioma, Recurrent Childhood Anaplastic Astrocytoma, Recurrent Childhood Anaplastic Oligoastrocytoma, Recurrent Childhood Anaplastic Oligodendroglioma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Giant Cell Glioblastoma, Recurrent Childhood Glioblastoma, Recurrent Childhood Gliomatosis Cerebri, Recurrent Childhood Gliosarcoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor | PALBOCICLIB ISETHIONATE | Its record names the disease | ClinicalTrials.gov |
| NCT02975882 | Nanoparticle Albumin-Bound Rapamycin, Temozolomide, and Irinotecan Hydrochloride in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | Phase 1 | 33 | 2023-03-30 | Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm | IRINOTECAN HYDROCHLORIDE, SIROLIMUS, TEMOZOLOMIDE | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT02808650 | Prexasertib in Treating Pediatric Patients With Recurrent or Refractory Solid Tumors | Phase 1 | 30 | 2023-12-20 | Childhood Solid Neoplasm, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm | PREXASERTIB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT03323034 | Pevonedistat, Irinotecan, and Temozolomide in Treating Patients With Recurrent or Refractory Solid Tumors or Lymphoma | Phase 1 | 30 | 2022-09-23 | Recurrent Lymphoma, Recurrent Malignant Solid Neoplasm, Recurrent Primary Central Nervous System Neoplasm, Refractory Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Primary Central Nervous System Neoplasm | IRINOTECAN, PEVONEDISTAT, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
| NCT02564198 | A Study of Ramucirumab (LY3009806) in Children With Refractory Solid Tumors | Phase 1 | 29 | 2021-08-17 | Pediatric Solid Tumor, Refractory Tumor, Recurrent Tumor, CNS Malignancies | RAMUCIRUMAB | Open Targets' reading of its record | ClinicalTrials.gov |
| NCT00876993 | Study of Irinotecan and Bevacizumab With Temozolomide in Refractory/Relapsed Central Nervous System (CNS) Tumors | Phase 1 | 26 | 2019-08-08 | Central Nervous System Tumors | BEVACIZUMAB, IRINOTECAN, TEMOZOLOMIDE | Its record names the disease | ClinicalTrials.gov |
1 to 10 of 58
See all 58 trialsComparisons in its trials2
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| 8 mg/kg Ramucirumab (Part A) vs 12 mg/kg Ramucirumab (Part A): Part A: Number of Participants With Dose Limiting Toxicities (DLTs): Maximum Tolerated Dose of Ramucirumab | 1 of 8 | 1 of 15 | 23 | NCT02564198 | Trial comparisons |
| Part A Dose Level 1: 30 mg/m^2 vs Part B Dose Level 2: 40 mg/m^2: Biomarker Response (CEA and Calcitonin) in Patients With Medullary Thyroid Cancer Treated With XL184 | 0 of 1 | 1 of 4 | 5 | NCT01709435 | Trial comparisons |
Papers from its trials61
The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
Data dates
The date of each source this release read.
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this disease from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0006130
GET https://conductscience.org/api/diseases/v1/MONDO_0006130/drugs?page=2